These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 18937906)
21. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540 [TBL] [Abstract][Full Text] [Related]
22. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027 [TBL] [Abstract][Full Text] [Related]
24. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Galor A; Perez VL; Hammel JP; Lowder CY Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615 [TBL] [Abstract][Full Text] [Related]
25. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]. de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652 [TBL] [Abstract][Full Text] [Related]
26. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526 [TBL] [Abstract][Full Text] [Related]
27. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634 [TBL] [Abstract][Full Text] [Related]
28. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target? Lu CY; Williams KM; Day RO Intern Med J; 2006 Jan; 36(1):19-27. PubMed ID: 16409309 [TBL] [Abstract][Full Text] [Related]
29. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031 [TBL] [Abstract][Full Text] [Related]
30. Adalimumab vs. etanercept in psoriasis. Downs AM Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064 [No Abstract] [Full Text] [Related]
35. Differentiating the efficacy of tumor necrosis factor inhibitors. Haraoui B J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457 [TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Bonafede MM; Gandra SR; Fox KM; Wilson KL J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705 [TBL] [Abstract][Full Text] [Related]
37. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282 [TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010. Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151 [TBL] [Abstract][Full Text] [Related]
39. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150 [TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]